Exscientia appoints Moelis & Company COO Elizabeth Crain to Board of Directors

pharmafile | February 10, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

AI-driven pharma-tech company Exscientia has appointed Elizabeth Crain to their Board of Directors.

She will use her new position to chair Exscientia’s audit committee and guide the company’s finance, market positioning, and governance activities.

Crain, who has been named as one of the 25 Most Powerful Women in Finance by American Banker magazine, is currently the COO and a Director at Moelis & Company, where she leads firm-wide strategy and the management of the global business.

Exscientia build dedicated AI systems to assist with drug design before progressing their AI-designed molecules into clinical settings.

Elizabeth Crain said, of her new appointment: “To work with one of the fastest growing innovators in biotech is extremely exciting. It is clear Exscientia is transforming drug discovery and has the potential to bring breakthroughs to patients far faster than historically possible.”

Andrew Hopkins, CEO of Exscientia also commented: “Elizabeth brings incredible corporate and market perspective to our company. We have been doubling our operations every year since inception and she knows what it takes to achieve growth while maintaining culture, discipline and focus.

“Elizabeth will also be a tremendous advisor as we extend our presence with the investor community and expand our US operations.” 

Exscientia have also added Ben Taylor to their Board of Directors, who will serve as the company’s Chief Financial Officer and Executive Director.


Related Content

No items found

Latest content